{
    "clinical_study": {
        "@rank": "28459", 
        "arm_group": [
            {
                "arm_group_label": "Sequence A \u21d2 B", 
                "arm_group_type": "Experimental", 
                "description": "Participants will receive sequence A = glycopyrronium + placebo to tiotropium during 28 days, followed by a 14 day washout period, then sequence B= tiotropium + placebo to glycopyrronium for 28 days."
            }, 
            {
                "arm_group_label": "Sequence B \u21d2 A", 
                "arm_group_type": "Experimental", 
                "description": "Participants will receive sequence B= tiotropium + placebo to glycopyrronium during 28 days, followed by a 14 day washout period, then sequence A= glycopyrronium + placebo to tiotropium for 28 days."
            }
        ], 
        "brief_summary": {
            "textblock": "This study purpose is to further study the profiles of glycopyrronium (NVA237) and\n      tiotropium during  the first hours after dosing and their impact on pulmonary function, COPD\n      symptoms and ability to perform daily activities by the patient."
        }, 
        "brief_title": "Effect of Glycopyrronium on Morning Symptoms and Pulmonary Function in Patients With Moderate to Severe COPD", 
        "completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "COPD", 
        "condition_browse": {
            "mesh_term": "Pulmonary Disease, Chronic Obstructive"
        }, 
        "detailed_description": {
            "textblock": "Randomized, multicenter, blinded, two-period cross-over design. Each treatment will last 28\n      days. All patients will receive both treatments in a cross-over design, with a wash-out\n      period of 14-19 days in between. The total duration of the study for each patient is\n      approximately 70 days (from randomization) plus 30 days of safety follow-up."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          -  Male and female adults aged \u2265 40 years.\n\n          -  Co-operative outpatients with a clinical diagnosis of moderate to severe COPD\n             confirmed by spirometry according to GOLD criteria 2013 and including all of the\n             following:  a) Current or ex-smokers who have a smoking history of at least 10 pack\n             years (e.g.10 pack years = 1 pack /day x 10 years or \u00bd pack/day x 20 years). An\n             ex-smoker may be defined as a subject who has not smoked for \u2265 6 months at Screening.\n              b) Patients with airflow limitation indicated by a post-bronchodilator FEV1 < 80%\n             and \u2265 40% of the predicted normal value at Visit 2 (Post- bronchodilator refers to\n             within 10-15 min of inhalation of 400 \u00b5g (4x100 \u00b5g) of salbutamol). c)\n             .Post-bronchodilator FEV1/FVC < 0.7 at Visit 2 (Post- bronchodilator refers to within\n             10-15 min of inhalation of 400 \u00b5g (4x100 \u00b5g) of salbutamol).\n\n          -  Patients with a COPD Assessment Test (CAT) score \u2265 10 at Visit 2.\n\n        Exclusion criteria:\n\n          -  Patients who have had a COPD exacerbation requiring systemic glucocorticosteroid\n             treatment or antibiotics and/or hospitalization in the 6 weeks prior to Visit 1. In\n             the event of an exacerbation occurring during the Screening period (Visits 1-2), the\n             patient must be discontinued from the study. The patient may be re-enrolled once the\n             inclusion/exclusion criteria are met. Only one re-enrollment is allowed.\n\n          -  Patients who have had a respiratory tract infection within 6 weeks prior to Visit 1.\n             Patients who develop a respiratory tract infection between Visit 1 and Visit 2 must\n             discontinue from the trial, but may be permitted to re-enrol at a later date once the\n             inclusion/exclusion criteria have been met. Only one re-enrollment is allowed.\n\n          -  Patients on any long-acting bronchodilator therapy. Those patients may enter the\n             study after bronchodilator withdrawal during a 10-day wash-out period (only rescue\n             salbutamol allowed as bronchodilator therapy during wash-out). Patients on fixed\n             combination of long acting \u03b22-agonists/inhaled corticosteroid (LABA/ICS) therapy\n             before screening must be switched to the equivalent dose of ICS monotherapy and\n             salbutamol as rescue.\n\n          -  Patients receiving any other prohibited COPD-related medications specified in Table\n             5-1 must undergo the required wash-out period prior to Visit 2.\n\n          -  Patients who have had a clinical history of asthma.\n\n          -  Patients with concomitant pulmonary disease, e.g. pulmonary tuberculosis or\n             clinically significant bronchiectasis.\n\n          -  Patients with alpha-1-antitrypsin deficiency.\n\n          -  Patients with contraindications for LAMA treatment including medical history of\n             symptomatic prostatic hypertrophy, bladder neck obstruction, narrow-angle glaucoma\n             and severe renal impairment (estimated glomerular filtration rate below 30\n             ml/min/1.73 m2) documented in the previous 6 months.\n\n          -  Patients with a history of unstable cardiovascular disease or arrhythmias including\n             atrial fibrillation/flutter or long QT syndrome or whose resting QTcF (calculated\n             according to Fridericia QT correction formula preferred, but Bazett acceptable) is\n             prolonged (\u2265 450 msec for males and \u2265 460 msec for females) at screening (Visit 1) or\n             baseline (Visit 2, baseline 1).\n\n          -  Concomitant use of agents known to prolong the QT interval unless it can be\n             permanently discontinued for the duration of study.\n\n          -  Patients contraindicated for treatment with, or having a history of reactions/\n             hypersensitivity to any of the following inhaled drugs, drugs of a similar class or\n             any component thereof: -anticholinergic agents - long and short acting 2 agonists\n             -sympathomimetic amines -excipients of the trial medication (lactose monohydrate\n             and/or magnesium estearate)\n\n          -  Patients whose body mass index (BMI) is less than 15 or greater than 40 kg/m2.\n\n          -  History of malignancy of any organ system (other than localized basal cell carcinoma\n             of the skin), treated or untreated, within the past 5 years, regardless of whether\n             there is evidence of local recurrence or metastases.\n\n        Other exclusion criteria may apply"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01959516", 
            "org_study_id": "CNVA237A3401"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Sequence A \u21d2 B", 
                    "Sequence B \u21d2 A"
                ], 
                "description": "Glycopyrronium capsule for inhalation once per day via SDDPI", 
                "intervention_name": "Glycopyrronium", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Sequence A \u21d2 B", 
                    "Sequence B \u21d2 A"
                ], 
                "description": "Tiotropium capsule for inhalation once per day via HandiHaler\u00ae device", 
                "intervention_name": "Tiotropium", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Sequence A \u21d2 B", 
                    "Sequence B \u21d2 A"
                ], 
                "description": "Placebo to glycopyrronium capsule for inhalation once per day via SDDPI", 
                "intervention_name": "Placebo to glycopyrronium", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Sequence A \u21d2 B", 
                    "Sequence B \u21d2 A"
                ], 
                "description": "Placebo to tiotropium capsule for inhalation once per day via HandiHaler\u00ae device", 
                "intervention_name": "Placebo to tiotropium", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Glycopyrrolate", 
                "Tiotropium"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "COPD, early morning symptoms", 
        "lastchanged_date": "January 27, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Berlin", 
                        "country": "Germany", 
                        "zip": "13156"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Berlin", 
                        "country": "Germany", 
                        "zip": "10119"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Berlin", 
                        "country": "Germany", 
                        "zip": "12099"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Geesthacht", 
                        "country": "Germany", 
                        "zip": "22502"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Halle", 
                        "country": "Germany", 
                        "zip": "06108"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Leipzig", 
                        "country": "Germany", 
                        "zip": "04275"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Leipzig", 
                        "country": "Germany", 
                        "zip": "04103"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Potsdam", 
                        "country": "Germany", 
                        "zip": "14467"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wiesbaden", 
                        "country": "Germany", 
                        "zip": "65187"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bologna", 
                        "country": "Italy", 
                        "state": "BO", 
                        "zip": "40138"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Firenze", 
                        "country": "Italy", 
                        "state": "FI", 
                        "zip": "50122"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Milano", 
                        "country": "Italy", 
                        "state": "MI", 
                        "zip": "20138"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sesto San Giovanni", 
                        "country": "Italy", 
                        "state": "Mi", 
                        "zip": "20099"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Orbassano", 
                        "country": "Italy", 
                        "state": "TO", 
                        "zip": "10043"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sevilla", 
                        "country": "Spain", 
                        "state": "Andalucia", 
                        "zip": "41013"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain", 
                        "state": "Catalu\u00f1a", 
                        "zip": "08041"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain", 
                        "zip": "08035"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Santa Cruz de Tenerife", 
                        "country": "Spain", 
                        "zip": "38009"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Zaragoza", 
                        "country": "Spain", 
                        "zip": "50009"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Blackpool", 
                        "country": "United Kingdom", 
                        "zip": "FY3 7EN"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bradford", 
                        "country": "United Kingdom", 
                        "zip": "BD9 6RJ"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cambridge", 
                        "country": "United Kingdom", 
                        "zip": "CB7 5JD"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cardiff", 
                        "country": "United Kingdom", 
                        "zip": "CF5 4AD"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Watford", 
                        "country": "United Kingdom", 
                        "zip": "WD25 0EA"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wishaw", 
                        "country": "United Kingdom", 
                        "zip": "ML2 0DP"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Germany", 
                "Italy", 
                "Spain", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "Multicenter, Randomized, Blinded, Two-period Cross-over Study to Assess the Effect of Glycopyrronium (44 Micrograms QD) Versus Tiotropium (18 Micrograms QD) on Morning Symptoms and Pulmonary Function in Patients With Moderate to Severe COPD", 
        "overall_contact": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone": "+41613241111"
        }, 
        "overall_contact_backup": {
            "last_name": "Novartis Pharmaceuticals"
        }, 
        "overall_official": {
            "affiliation": "Novartis Pharmaceuticals", 
            "last_name": "Novartis Pharmaceuticals", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "Italy: Ministry of Health", 
                "Germany: Ministry of Health", 
                "Spain: Ministry of Health", 
                "United Kingdom: National Institute for Health Research"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Forced Expiratory Volume in 1 second (FEV1) Area Under the Curve (AUC) will measured via spirometry and calculated from 0 to 4 hours post-dose on day 1 and week 4 of study treatment.", 
            "measure": "Forced Expiratory Volume in 1 second (FEV1) AUC0-4h after first dose of treatment.", 
            "safety_issue": "No", 
            "time_frame": "day 1 (baseline) and week 4"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01959516"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Comparison of symptoms outcome between glycopyrronium QD versus tiotropium QD will be conducted via the PROMorning COPD Symptoms questionnaire. This questionnaire will be completed by participants at waking-up, pre-inhalation of study treatment (at home), and they will complete Part 2 of PRO-Morning COPD Symptoms questionnaire at site, 3hours post-inhalation of study treatment.", 
            "measure": "Comparison of glycopyrronium QD versus tiotropium QD on symptoms outcome", 
            "safety_issue": "No", 
            "time_frame": "day 1 (baseline)  and week 4"
        }, 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}